Advertisement
BLCO or IDXX or SNN
Which Stock Would AI Choose? Bausch + Lomb Corporation (BLCO) vs. IDEXX Laboratories, Inc. (IDXX) vs. Smith & Nephew plc (SNN) Stock Comparison
Key Takeaways
- BLCO delivered Q2 2026 revenue of $1.39 billion, exceeding estimates by 1.7% with 9.1% year-over-year growth, and raised full-year guidance amid broad-based segment performance.
- IDXX reported strong Q1 2026 results with 14% reported revenue growth and raised its full-year outlook; investors await Q2 results scheduled for August 4, 2026.
- SNN beat Q1 expectations, launched a $500 million share buyback program, and received FDA De Novo classification for its TESSA Spatial Surgery System in recent weeks.
- Sector exposure differs sharply: BLCO focuses on eye health, IDXX on veterinary diagnostics, and SNN on orthopedics and sports medicine.
- Recent market activity shows BLCO with positive post-earnings momentum, while IDXX and SNN trade ahead of upcoming quarterly reports.
- Valuation sensitivity and growth drivers vary, with IDXX emphasizing recurring diagnostics revenue and SNN highlighting share repurchases and product innovation.
Introduction
This comparison examines three healthcare stocks—BLCO, IDXX, and SNN—that operate in distinct niches of the medical sector. Bausch + Lomb Corporation provides eye health products, IDEXX Laboratories, Inc. specializes in veterinary diagnostics and software, and Smith & Nephew plc focuses on orthopedic and wound care devices. The analysis highlights recent performance trends, business models, and market positioning relevant to investors and traders evaluating relative strength in the current environment. It offers factual context for those assessing sector exposure, earnings momentum, and operational developments across these names.
BLCO Overview and Recent Performance
Bausch + Lomb Corporation develops and markets vision care products, ophthalmic pharmaceuticals, and surgical devices. In recent market activity, the company reported second-quarter 2026 revenue of $1.39 billion, representing 9.1% year-over-year growth and a modest beat of analyst estimates. Management raised full-year 2026 revenue guidance following broad-based gains across segments and improved adjusted EBITDA performance. Stock price behavior reflected a positive reaction to the results, with shares advancing in the immediate aftermath. Sentiment has been supported by consistent execution in core eye health categories amid stable demand for contact lenses, lens care, and surgical solutions.
IDXX Overview and Recent Performance
IDEXX Laboratories, Inc. provides diagnostic and software solutions primarily for companion animal veterinary practices, along with livestock, poultry, and water testing products. The company posted first-quarter 2026 revenue growth of 14% as reported and 11% organic, driven by companion animal group diagnostics recurring revenue. It raised its full-year 2026 revenue and earnings per share outlook. In recent weeks, attention has centered on the upcoming second-quarter results, set for release on August 4, 2026, followed by an Investor Day on August 13. Price performance has been influenced by anticipation of continued organic growth in high-margin recurring revenue streams.
SNN Overview and Recent Performance
Smith & Nephew plc manufactures orthopedic reconstruction, sports medicine, and wound management products. The company exceeded first-quarter 2026 sales expectations and announced a $500 million share repurchase program, signaling confidence in cash flow generation. Recent developments include FDA De Novo classification for the TESSA Spatial Surgery System, aimed at advancing personalized planning in sports medicine. Shares have traded in a range ahead of second-quarter and first-half results scheduled for August 4. Market sentiment reflects positioning around new technology adoption and capital return initiatives.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that features select AI trading bots optimized for prevailing market conditions. While hundreds of AI trading bots are available across thousands of tickers, only those demonstrating strong alignment with current trends, risk parameters, and performance metrics earn placement in this highlighted area. Bots in the section exhibit varied trading styles, strategies, timeframes, and statistical profiles, including different win rates, drawdowns, and ticker coverage. Users can review detailed performance data and configurations to identify options suited to specific objectives. Explore the full selection on the Trending AI Robots page for additional insights.
Head-to-Head Comparison
Business models diverge significantly: BLCO generates revenue from consumer and professional eye health products with exposure to elective procedures; IDXX benefits from recurring diagnostics revenue in veterinary settings; and SNN relies on implant and device sales in orthopedics with emerging digital surgery tools. Growth drivers include BLCO’s segment expansion and guidance lifts, IDXX’s organic diagnostics momentum, and SNN’s product launches plus buybacks. Recent momentum favors BLCO following its earnings beat, while IDXX and SNN face near-term catalysts tied to upcoming reports. Risk factors encompass regulatory and reimbursement pressures for all three, with valuation sensitivity higher for growth-oriented names like IDXX and operational leverage differing by sector exposure. Market sentiment remains constructive on innovation and capital allocation across the group.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, guidance updates, and relative positioning ahead of catalysts, Tickeron’s AI models currently assign a higher probabilistic weighting to BLCO due to its demonstrated revenue beat and raised outlook in the most recent reporting period. IDXX and SNN show solid underlying trends but await confirmation from pending quarterly results. This assessment reflects trend stability and near-term visibility rather than absolute rankings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLCO’s FA Score shows that 1 FA rating(s) are green whileIDXX’s FA Score has 1 green FA rating(s), and SNN’s FA Score reflects 1 green FA rating(s).
- BLCO’s FA Score: 1 green, 4 red.
- IDXX’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLCO’s TA Score shows that 4 TA indicator(s) are bullish while IDXX’s TA Score has 7 bullish TA indicator(s), and SNN’s TA Score reflects 4 bullish TA indicator(s).
- BLCO’s TA Score: 4 bullish, 5 bearish.
- IDXX’s TA Score: 7 bullish, 2 bearish.
- SNN’s TA Score: 4 bullish, 5 bearish.
Price Growth
BLCO (@Pharmaceuticals: Other) experienced а -0.77% price change this week, while IDXX (@Medical Specialties) price change was +4.94% , and SNN (@Medical/Nursing Services) price fluctuated -4.59% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.28%. For the same industry, the average monthly price growth was +5.47%, and the average quarterly price growth was +2.65%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +5.89%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was -8.72%.
Reported Earning Dates
BLCO is expected to report earnings on Nov 04, 2026.
IDXX is expected to report earnings on Nov 03, 2026.
SNN is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+4.28% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+5.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| BLCO | IDXX | SNN | |
| Capitalization | 5.93B | 46.2B | 12.5B |
| EBITDA | 735M | 1.56B | 1.53B |
| Gain YTD | -1.756 | -13.282 | -6.838 |
| P/E Ratio | N/A | 41.23 | 20.48 |
| Revenue | 5.32B | 4.45B | 6.16B |
| Total Cash | 367M | 201M | 419M |
| Total Debt | 5.12B | 1.11B | 3.45B |
IDXX | SNN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 16 | 77 | |
PRICE GROWTH RATING 1..100 | 54 | 60 | |
P/E GROWTH RATING 1..100 | 79 | 88 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (3) in the Medical Specialties industry is significantly better than the same rating for IDXX (80). This means that SNN’s stock grew significantly faster than IDXX’s over the last 12 months.
SNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IDXX (100). This means that SNN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SNN (77). This means that IDXX’s stock grew somewhat faster than SNN’s over the last 12 months.
IDXX's Price Growth Rating (54) in the Medical Specialties industry is in the same range as SNN (60). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
IDXX's P/E Growth Rating (79) in the Medical Specialties industry is in the same range as SNN (88). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
| BLCO | IDXX | SNN | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 73% | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 67% | 3 days ago 59% | 3 days ago 66% |
| Momentum ODDS (%) | 3 days ago 74% | 3 days ago 55% | 3 days ago 58% |
| MACD ODDS (%) | 3 days ago 62% | 3 days ago 65% | 3 days ago 60% |
| TrendWeek ODDS (%) | 3 days ago 70% | 3 days ago 59% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 73% | 3 days ago 53% | 3 days ago 57% |
| Advances ODDS (%) | 13 days ago 65% | 6 days ago 59% | 12 days ago 57% |
| Declines ODDS (%) | 6 days ago 68% | 18 days ago 70% | 5 days ago 57% |
| BollingerBands ODDS (%) | 3 days ago 78% | 3 days ago 77% | 3 days ago 44% |
| Aroon ODDS (%) | 3 days ago 77% | 3 days ago 54% | 3 days ago 53% |
Advertisement
BLCO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BLCO has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BLCO jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To BLCO | 1D Price Change % | ||
|---|---|---|---|---|
| BLCO | 100% | +2.63% | ||
| ICUI - BLCO | 46% Loosely correlated | +10.93% | ||
| CRL - BLCO | 45% Loosely correlated | +0.75% | ||
| COO - BLCO | 44% Loosely correlated | +1.24% | ||
| MTD - BLCO | 44% Loosely correlated | +0.58% | ||
| RVTY - BLCO | 44% Loosely correlated | +0.37% | ||
More | ||||
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | -0.56% | ||
| ALGN - IDXX | 50% Loosely correlated | +2.71% | ||
| SYK - IDXX | 48% Loosely correlated | +0.47% | ||
| BLCO - IDXX | 45% Loosely correlated | +2.63% | ||
| SNN - IDXX | 44% Loosely correlated | +1.41% | ||
| RVTY - IDXX | 41% Loosely correlated | +0.37% | ||
More | ||||